Multiple Myeloma Presenting as Autoimmune Hemolytic Anemia: Bortezomib as Potential Therapy for Autoimmune Hemolytic Anemia Refractory to Standard Corticosteroid Therapy
Clinical Reviews & Cases · 2020
DOI: 10.33425/2689-1069.1019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Reviews & Cases, 2020. Verfasst von Joehar Hamdan und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hamdan, J., Truhlar, A., Rudolph, E. H., & Mahafzah, M. (2020). Multiple Myeloma Presenting as Autoimmune Hemolytic Anemia: Bortezomib as Potential Therapy for Autoimmune Hemolytic Anemia Refractory to Standard Corticosteroid Therapy. Clinical Reviews & Cases. https://doi.org/10.33425/2689-1069.1019
Vancouver
Hamdan J, Truhlar A, Rudolph EH, Mahafzah M. Multiple Myeloma Presenting as Autoimmune Hemolytic Anemia: Bortezomib as Potential Therapy for Autoimmune Hemolytic Anemia Refractory to Standard Corticosteroid Therapy. Clinical Reviews & Cases. 2020. doi:10.33425/2689-1069.1019
BibTeX
@article{Hamdan2020,
author = {Hamdan, Joehar and Truhlar, Ashley and Rudolph, Earl H and Mahafzah, Mahmoud},
title = {Multiple Myeloma Presenting as Autoimmune Hemolytic Anemia: Bortezomib as Potential Therapy for Autoimmune Hemolytic Anemia Refractory to Standard Corticosteroid Therapy},
journal = {Clinical Reviews & Cases},
year = {2020},
doi = {10.33425/2689-1069.1019}
}
EUVIMED